Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 545

1.

Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma.

Hu Y, Liu H, Fang C, Li C, Xhyliu F, Dysert H, Bodo J, Habermehl G, Russell BE, Li W, Chappell M, Jiang X, Ondrejka SL, Hsi ED, Maciejewski JP, Yi Q, Anderson KC, Munshi NC, Ao G, Valent JN, Lin J, Zhao J.

Cancer Res. 2020 Mar 19. pii: canres.1077.2019. doi: 10.1158/0008-5472.CAN-19-1077. [Epub ahead of print]

PMID:
32193289
2.

YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma.

Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Tai YT, Anderson KC, Qiu L, Munshi NC.

Blood. 2020 Mar 18. pii: blood.2019004147. doi: 10.1182/blood.2019004147. [Epub ahead of print]

PMID:
32187357
3.

c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.

Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H, Masszi T, Viterbo L, Pour L, Ganly P, Cavo M, Langer C, Kumar SK, Rajkumar SV, Keats JJ, Berg D, Lin J, Li B, Badola S, Shen L, Zhang J, Esseltine DL, Luptakova K, van de Velde H, Richardson PG, Moreau P.

Eur J Haematol. 2020 Mar 7. doi: 10.1111/ejh.13405. [Epub ahead of print]

PMID:
32145111
4.

Author Correction: Using Gjd3-CreEGFP mice to examine atrioventricular node morphology and composition.

Bhattacharyya S, Duan J, Wang L, Li B, Bhakta M, Fernandez-Perez A, Hon GC, Munshi NV.

Sci Rep. 2020 Feb 28;10(1):4069. doi: 10.1038/s41598-020-60915-5.

5.

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.

Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Dan Rozelle, Danziger SA, Ratushny A; Multiple Myeloma DREAM Consortium, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J.

Leukemia. 2020 Feb 14. doi: 10.1038/s41375-020-0742-z. [Epub ahead of print]

PMID:
32060406
6.

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.

Xing L, Lin L, Yu T, Li Y, Cho SF, Liu J, Wen K, Hsieh PA, Kinneer K, Munshi N, Anderson KC, Tai YT.

Leukemia. 2020 Feb 14. doi: 10.1038/s41375-020-0745-9. [Epub ahead of print]

PMID:
32060401
7.

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.

Morelli E, Gullà A, Rocca R, Federico C, Raimondi L, Malvestiti S, Agosti V, Rossi M, Costa G, Giavaresi G, Azab KA, Cagnetta A, Cea M, Tagliaferri P, Neri A, Munshi NC, Viglietto G, Tassone P, Amodio N.

Cancers (Basel). 2020 Jan 30;12(2). pii: E320. doi: 10.3390/cancers12020320. Review.

8.

Development of the Cardiac Conduction System.

Bhattacharyya S, Munshi NV.

Cold Spring Harb Perspect Biol. 2020 Jan 27. pii: a037408. doi: 10.1101/cshperspect.a037408. [Epub ahead of print]

PMID:
31988140
9.

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.

Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC.

Leukemia. 2020 Jan 16. doi: 10.1038/s41375-020-0705-4. [Epub ahead of print]

PMID:
31949267
10.

A lower affinity to cytosolic proteins reveals VDAC3 isoform-specific role in mitochondrial biology.

Queralt-Martín M, Bergdoll L, Teijido O, Munshi N, Jacobs D, Kuszak AJ, Protchenko O, Reina S, Magrì A, De Pinto V, Bezrukov SM, Abramson J, Rostovtseva TK.

J Gen Physiol. 2020 Feb 3;152(2). pii: e201912501. doi: 10.1085/jgp.201912501.

PMID:
31935282
11.

Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.

Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O.

JAMA Oncol. 2019 Dec 12. doi: 10.1001/jamaoncol.2019.4659. [Epub ahead of print]

PMID:
31830214
12.

Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma.

Alagpulinsa DA, Kumar S, Talluri S, Nanjappa P, Buon L, Chakraborty C, Samur MK, Szalat R, Shammas MA, Munshi NC.

Blood Adv. 2019 Dec 10;3(23):3968-3972. doi: 10.1182/bloodadvances.2019000181. No abstract available.

13.

Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.

Sewastianik T, Guerrera ML, Adler K, Dennis PS, Wright K, Shanmugam V, Huang Y, Tanton H, Jiang M, Kofides A, Demos MG, Dalgarno A, Patel NA, Nag A, Pinkus GS, Yang G, Hunter ZR, Jarolim P, Munshi NC, Treon SP, Carrasco RD.

Blood Adv. 2019 Nov 12;3(21):3360-3374. doi: 10.1182/bloodadvances.2019000588.

14.

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.

An G, Yan Y, Xu Y, Mao X, Liu J, Fan H, Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D, Zhao Y, Yuan C, Du X, Wang J, Cheng T, Tai YT, Munshi NC, Qiu L.

Leukemia. 2020 Feb;34(2):578-588. doi: 10.1038/s41375-019-0590-x. Epub 2019 Oct 7.

PMID:
31591469
15.

Structure prediction and molecular docking studies of aromatic hydrocarbon sensing proteins TbuT, HbpR and PhnR to detect priority pollutants.

Patel R, Chudasama R, Solanki R, Patel P, Parmar K, Munshi NS.

J Environ Sci Health A Tox Hazard Subst Environ Eng. 2020;55(2):126-141. doi: 10.1080/10934529.2019.1672457. Epub 2019 Sep 29.

PMID:
31566066
16.

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL.

Biol Blood Marrow Transplant. 2020 Jan;26(1):e7-e15. doi: 10.1016/j.bbmt.2019.09.015. Epub 2019 Sep 14. Review.

PMID:
31526843
17.

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG.

Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4.

PMID:
31456261
18.

Genomic landscape and chronological reconstruction of driver events in multiple myeloma.

Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, Mitchell TJ, Fullam A, Gonzalez S, Szalat R, Abascal F, Rodriguez-Martin B, Samur MK, Glodzik D, Roncador M, Fulciniti M, Tai YT, Minvielle S, Magrangeas F, Moreau P, Corradini P, Anderson KC, Tubio JMC, Wedge DC, Gerstung M, Avet-Loiseau H, Munshi N, Campbell PJ.

Nat Commun. 2019 Aug 23;10(1):3835. doi: 10.1038/s41467-019-11680-1.

19.

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.

Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC.

Leukemia. 2020 Jan;34(1):210-223. doi: 10.1038/s41375-019-0540-7. Epub 2019 Aug 19. Erratum in: Leukemia. 2020 Jan 16;:.

PMID:
31427721
20.

Development of fluorescent protein-based biosensing strains: A new tool for the detection of aromatic hydrocarbon pollutants in the environment.

Patel R, Zaveri P, Mukherjee A, Agarwal PK, More P, Munshi NS.

Ecotoxicol Environ Saf. 2019 Oct 30;182:109450. doi: 10.1016/j.ecoenv.2019.109450. Epub 2019 Jul 23.

PMID:
31349104
21.

Author Correction: A practical guide for mutational signature analysis in hematological malignancies.

Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L, Royo R, Ziccheddu B, Puente XS, Avet-Loiseau H, Campbell PJ, Nik-Zainal S, Campo E, Munshi N, Bolli N.

Nat Commun. 2019 Jul 25;10(1):3431. doi: 10.1038/s41467-019-11468-3.

22.

Monoclonal Gammopathy May Be of Unpredictable Significance.

Munshi NC, Jagannath S, Avet-Loiseau H.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1580. [Epub ahead of print] No abstract available.

PMID:
31318381
23.

A practical guide for mutational signature analysis in hematological malignancies.

Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L, Royo R, Ziccheddu B, Puente XS, Avet-Loiseau H, Campbell PJ, Nik-Zainal S, Campo E, Munshi N, Bolli N.

Nat Commun. 2019 Jul 5;10(1):2969. doi: 10.1038/s41467-019-11037-8. Erratum in: Nat Commun. 2019 Jul 25;10(1):3431.

24.

Rational Reprogramming of Cellular States by Combinatorial Perturbation.

Duan J, Li B, Bhakta M, Xie S, Zhou P, Munshi NV, Hon GC.

Cell Rep. 2019 Jun 18;27(12):3486-3499.e6. doi: 10.1016/j.celrep.2019.05.079.

25.

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Adamia S, Abiatari I, Amin SB, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi NC, Anderson KC.

Leukemia. 2020 Jan;34(1):167-179. doi: 10.1038/s41375-019-0498-5. Epub 2019 Jun 10.

26.

Hand2 Selectively Reorganizes Chromatin Accessibility to Induce Pacemaker-like Transcriptional Reprogramming.

Fernandez-Perez A, Sathe AA, Bhakta M, Leggett K, Xing C, Munshi NV.

Cell Rep. 2019 May 21;27(8):2354-2369.e7. doi: 10.1016/j.celrep.2019.04.077.

27.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J.

Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15. No abstract available.

PMID:
31090915
28.

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.

Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL.

Blood. 2019 Jul 11;134(2):160-170. doi: 10.1182/blood.2019000789. Epub 2019 May 1.

PMID:
31043423
29.

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN.

N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.

PMID:
31042825
30.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):332-344. doi: 10.1016/j.clml.2019.02.004. Epub 2019 Feb 20. Review.

PMID:
31023594
31.

With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.

Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, Rivero G, Zimolzak A, Pyarajan S, Do N, Brophy M, Munshi NC.

Blood. 2019 Jun 13;133(24):2615-2618. doi: 10.1182/blood.2019000406. Epub 2019 Apr 19. No abstract available.

PMID:
31003998
32.

PAN-INTACT enables direct isolation of lineage-specific nuclei from fibrous tissues.

Bhattacharyya S, Sathe AA, Bhakta M, Xing C, Munshi NV.

PLoS One. 2019 Apr 2;14(4):e0214677. doi: 10.1371/journal.pone.0214677. eCollection 2019.

33.

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Jagannath S, Heffner LT Jr, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380. doi: 10.1016/j.clml.2019.02.006. Epub 2019 Feb 21.

PMID:
30930134
34.

Deciphering the chronology of copy number alterations in Multiple Myeloma.

Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK.

Blood Cancer J. 2019 Mar 26;9(4):39. doi: 10.1038/s41408-019-0199-3.

35.

The roles of homologous recombination and the immune system in the genomic evolution of cancer.

Nandi B, Talluri S, Kumar S, Yenumula C, Gold JS, Prabhala R, Munshi NC, Shammas MA.

J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000282. Epub 2018 Oct 1.

36.
37.

Using Gjd3-CreEGFP mice to examine atrioventricular node morphology and composition.

Bhattacharyya S, Duan J, Wang L, Li B, Bhakta M, Fernandez-Perez A, Hon GC, Munshi NV.

Sci Rep. 2019 Feb 14;9(1):2106. doi: 10.1038/s41598-019-38683-8. Erratum in: Sci Rep. 2020 Feb 28;10(1):4069.

38.

Novel Agents in Multiple Myeloma.

Szalat R, Munshi NC.

Cancer J. 2019 Jan/Feb;25(1):45-53. doi: 10.1097/PPO.0000000000000355. Review.

39.

Introduction by the Guest Editor: At a Crossroad to Cure: From Molecule to Management Strategies in Multiple Myeloma.

Munshi NC.

Cancer J. 2019 Jan/Feb;25(1):1. doi: 10.1097/PPO.0000000000000357. Review. No abstract available.

40.

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.

Fulciniti M, Lin CY, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC.

Cell Rep. 2018 Dec 26;25(13):3693-3705.e6. doi: 10.1016/j.celrep.2018.12.016.

41.

pouC Regulates Expression of bmp4 During Atrioventricular Canal Formation in Zebrafish.

Bhakta M, Padanad MS, Harris JP, Lubczyk C, Amatruda JF, Munshi NV.

Dev Dyn. 2019 Feb;248(2):173-188. doi: 10.1002/dvdy.2. Epub 2018 Dec 10.

42.

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14).

Cleynen A, Samur M, Perrot A, Buisson L, Maheo S, Fulciniti M, Attal M, Munshi N, Avet-Loiseau H, Corre J.

Blood. 2018 Dec 27;132(26):2778-2780. doi: 10.1182/blood-2018-09-876433. Epub 2018 Nov 14. No abstract available.

43.

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.

44.

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP.

Blood Adv. 2018 Nov 13;2(21):2937-2946. doi: 10.1182/bloodadvances.2018022962.

45.

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S.

Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5.

46.

Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance.

Kumar S, Talluri S, Pal J, Yuan X, Lu R, Nanjappa P, Samur MK, Munshi NC, Shammas MA.

Blood Cancer J. 2018 Sep 25;8(10):92. doi: 10.1038/s41408-018-0129-9.

47.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

Bødker JS, Brøndum RF, Schmitz A, Schönherz AA, Jespersen DS, Sønderkær M, Vesteghem C, Due H, Nørgaard CH, Perez-Andres M, Samur MK, Davies F, Walker B, Pawlyn C, Kaiser M, Johnson D, Bertsch U, Broyl A, van Duin M, Shah R, Johansen P, Nørgaard MA, Samworth RJ, Sonneveld P, Goldschmidt H, Morgan GJ, Orfao A, Munshi N, Johnson HE, El-Galaly T, Dybkær K, Bøgsted M.

Blood Adv. 2018 Sep 25;2(18):2400-2411. doi: 10.1182/bloodadvances.2018018564. Erratum in: Blood Adv. 2019 Mar 26;3(6):874.

48.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.

49.

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.

Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter Z, Anderson KC, Treon SP, Munshi NC, Fulciniti M.

Clin Cancer Res. 2019 Jan 1;25(1):369-377. doi: 10.1158/1078-0432.CCR-18-1776. Epub 2018 Sep 11.

50.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.

Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.

Supplemental Content

Loading ...
Support Center